Abstract
Significant Response to Palbociclib Plus Lenvatinib as Second-line Treatment for CDKN2A/2B Deletion Intrahepatic Cholangiocarcinoma: A Case Report
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have